IUC-T Oncopole, Unité de Génomique du Myélome, Toulouse, France.
Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
Blood. 2024 May 16;143(20):2025-2028. doi: 10.1182/blood.2024023880.
Smoldering multiple myeloma (MM) is an asymptomatic clonal plasma cell condition considered as a premalignant entity that may evolve over time to symptomatic MM. Based on a "poorly defined" risk of progression, some well-intended investigators proposed prospective interventional trials for these individuals. We believe this may be a harmful intervention and favor a close "wait and watch" approach and rather enroll these patients in dedicated observational biological studies aiming to better identify patients who will evolve to MM, based on their plasma cells' biology, including genomics, epigenetics, and the immune microenvironment.
冒烟型多发性骨髓瘤（MM）是一种无症状的克隆浆细胞疾病，被认为是一种癌前实体，随着时间的推移可能会发展为有症状的 MM。基于“定义不明确”的进展风险，一些出于好意的研究人员为这些患者提出了前瞻性干预试验。我们认为这可能是一种有害的干预措施，因此更倾向于密切的“等待和观察”方法，并将这些患者纳入专门的观察性生物学研究中，旨在根据其浆细胞的生物学特性，包括基因组学、表观遗传学和免疫微环境，更好地识别将发展为 MM 的患者。
